Classifications: anthelmintic; Therapeutic: anthelmintic
Pregnancy Category: C
500 mg chewable tablets
Has a wide spectrum of anthelmintic activity. Inhibits helminth-specific enzyme fumarate reductase.
Suppresses production of eggs or larvae by some parasites and may inhibit subsequent development of eggs or larvae passed
in feces. Demonstrates antiinflammatory, antipyretic, and analgesic effects.
Enterobiasis (pinworm infestation), ascariasis (roundworm), strongyloidiasis (threadworm), cutaneous larva migrans (creeping
eruption), and hookworm infestations caused by Ancyclostoma duodenale or Necator americanus. Used during invasive stage of trichinosis to relieve symptoms and for mixed helminthic infestations.
Hypersensivity to thiabendazole; pregnancy (category C); lactation.
Liver or kidney dysfunction; when vomiting can be dangerous, severe dehydration or malnutrition; anemia; children weighing
Route & Dosage
|Enterobiasis, Ascariasis, Strongyloidiasis, Hookworm
Adult: PO <70 kg, 25 mg/kg b.i.d. x 2 d; >70 kg, 1.5 g b.i.d. (max: 3 g/d) x 2 d
Child (1470 kg): PO 25 mg/kg b.i.d. x 2 d
- Give after meals. Chewable tablets must be chewed thoroughly before swallowing.
- Shake suspension well before pouring.
Adverse Effects (≥1%)CNS:
drowsiness, headache. CV:
Hypotension, bradycardia. GI: Anorexia, nausea, vomiting,
epigastric distress, jaundice
, cholestasis, parenchymal liver damage, diarrhea, perianal rash. Urogenital:
Malodor of urine, crystalluria, hematuria, nephrotoxicity, enuresis. Metabolic:
Transient rise in AST, transient leukopenia, hypersensitivity, hyperglycemia. Skin:
Readily from GI tract. Peak:
12 h. Metabolism:
In liver. Elimination:
>90% in urine; 5% in feces.
Assessment & Drug Effects
- Provide supportive treatment prior to therapy if patient is anemic, dehydrated, or malnourished.
- Adverse effects generally occur 34 h after administration, are mild, and last for 28 h. Incidence tends to be
related to dose and duration of treatment.
- Discontinued immediately with S&S of hypersensitivity: Fever, facial flush, chills, conjunctival infection, skin rashes,
or erythema multiforme (including Stevens-Johnson syndrome), which can be fatal.
Patient & Family Education
- Do not drive or engage in potentially hazardous activities until response to drug is known. CNS adverse effects occur frequently.